All
Investigational BTK Inhibitor Sparks Responses in Patients with Mantle Cell Lymphoma
December 26th 2018The investigational targeted drug zanubrutinib (BGB-3111) appeared to be highly active, inducing an overall response rate of 83.5 percent in patients with relapsed/refractory mantle cell lymphoma, who were treated in a single-arm, open-label, multicenter, phase 2 trial.
FDA Approves New Drug Regimen for Acute Lymphoblastic Leukemia
December 21st 2018The Food and Drug Administration approved Asparlas (calaspargase pegol-mknl) as a component of a chemotherapy regimen to treat adult and pediatric patients with acute lymphoblastic leukemia (ALL), according to the agency.
FDA Approves Keytruda for Merkel Cell Carcinoma
December 20th 2018The Food and Drug Administration (FDA) granted accelerated approval to Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, according to the agency.
FDA Approves Diagnostic Tool for BRCA-Mutant Ovarian Cancer
December 19th 2018The Food and Drug Administration (FDA) approved BRACAnalysis CDx to be used to identify patients with advanced ovarian cancer who have germline BRCA mutations and are eligible for first line treatment with Lynparza (olaparib) after responding to platinum-based chemotherapy.
Living in the Land of the Healthy
December 19th 2018When a diagnosis begins to improve, it is hard to reconcile your identity as a patient with your identity as a whole. Grappling with questions of who you are after having been diagnosed with something life altering can be both profound and challenging, and leave you a bit, well, ambivalent.
Crossover Study Offers Additional Line of Therapy for Patients with Relapsed CLL/SLL
December 18th 2018Single agent Copiktra (duvelisib) induced robust, durable responses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who experienced disease progression after treatment with Arzerra (ofatumumab).
Billionaire Philanthropist Discusses His Institute's Work to Perfect Cancer Immunotherapy
December 18th 2018Immunotherapy has become a buzzword in the cancer community, but to Sean Parker it’s much more. The 39-year-old billionaire is intensely focused on the promise of immunotherapy, and has become a major force in helping to drive its potential to cure cancers.
FDA Approves Herceptin Biosimilar for Breast Cancer Treatment
December 15th 2018The FDA has approved Herzuma (trastuzumab-pkrb) (Herzuma) as a biosimilar to Herceptin (trastuzumab, Genentech). Trastuzumab-pkrb is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer.
FDA Approves Medication to Treat Pediatric Patients With Immune Thrombocytopenia
December 15th 2018The Food and Drug Administration has approved Nplate for pediatric patients 1 year of age and older with immune thrombocytopenia who have had an insufficient response to medications, such as corticosteroids,or surgery to remove the spleen.
Frontline BTK Inhibitor Regimen Improves Outcomes in CLL/SLL
December 14th 2018Frontline use of Imbruvica (ibrutinib) in combination with Gazyva (obinutuzumab) significantly reduced the risk for disease progression or death among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), especially in those with high-risk disease.
Cancer Survivors Wait for the Other Shoe to Drop
December 14th 2018I try so hard to be positive, but in the back of my mind, I am constantly waiting for the other shoe to drop, for my blood counts to worsen, for the results of the next bone marrow biopsy to be haywire, for the chemo with its side effects to be administered, intensified or changed.